Evidence map›Paper›PMID 37351703›Full record

Trial reportGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2023

Long-term outcomes of a phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumors of the stomach.

Seong-Ho Kong, Yukinori Kurokawa, Jeong-Hwan Yook, Haruhiko Cho, Oh-Kyoung Kwon, Toru Masuzawa, Kyung Hee Lee, Sohei Matsumoto, Young Soo Park, Hiroshi Honda and 10 more

Abstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Seong-Ho Kong *Department of Surgery, Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine Cancer Research Institute, 101, Daehak-ro, Jongno-gu, Seoul, 0380, South Korea.
Yukinori Kurokawa *Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Jeong-Hwan YookDepartment of Surgery, University of Ulsan College of Medicine Asan Medical Center, Seoul, South Korea.
Haruhiko ChoDepartment of Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Oh-Kyoung KwonDepartment of Surgery, Kyungpook National University School of Medicine, Kyungpook National University Chilgok Hospital, Daegu, South Korea.
Toru MasuzawaDepartment of Surgery, Osaka Police Hospital, Osaka, Japan.
Kyung Hee LeeDepartment of Hemato-Oncology, Yeungnam University College of Medicine, Daegu, South Korea.
Sohei MatsumotoDepartment of Surgery, Nara Medical University, Nara, Japan.
Young Soo ParkDepartment of Pathology, University of Ulsan College of Medicine Asan Medical Center, Seoul, South Korea.
Hiroshi HondaDepartment of Surgery, Sendai Open Hospital, Sendai, Japan.
Seung-Wan RyuDepartment of Surgery, Keimyung University Dongsan Hospital, Daegu, South Korea.
Takashi IshikawaDepartment of Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Hye Jin KangDepartment of Internal Medicine, Korea Institute of Radiological & Medical Sciences, Korea Cancer Center Hospital, Seoul, South Korea.
Kazuhito NabeshimaDepartment of Surgery, Tokai University, Hiratsuka, Kanagawa, Japan.
Seock-Ah ImDepartment of Internal Medicine, Seoul National University Hospital and Seoul National University College of Medicine Cancer Research Institute, Seoul, South Korea.
Toshio ShimokawaClinical Study Support Center, Wakayama Medical University Hospital, Wakayama, Japan.
Yoon-Koo KangDepartment of Oncology, University of Ulsan College of Medicine Asan Medical Center, Seoul, South Korea.
Seiichi HirotaDepartment of Surgical Pathology, Hyogo Medical University School of Medicine, Nishinomiya, Japan.
Han-Kwang YangDepartment of Surgery, Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine Cancer Research Institute, 101, Daehak-ro, Jongno-gu, Seoul, 0380, South Korea. hkyang@snu.ac.kr.ORCID 0000-0003-3495-3048
Toshirou NishidaDepartment of Surgery, Japan Community Health Care Organization Osaka Hospital, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeoadjuvant treatment is recommended for large GISTs due to their friability and risk of extensive operations; however, studies on the indications and long-term results of this approach are lacking.

methodsPatients with large (≥ 10 cm) gastric GISTs were enrolled from multiple centers in Korea and Japan after a pathologic confirmation of c-KIT ( +) GISTs. Imatinib (400 mg/d) was given for 6-9 months preoperatively, and R0 resection was intended. Postoperative imatinib was given for at least 12 months and recommended for 3 years.

resultsA total of 56 patients were enrolled in this study, with 53 patients receiving imatinib treatment at least once and 48 patients undergoing R0 resection. The 5-year overall survival and progression-free survival rates were 94.3% and 61.6%, respectively. Even patients with stable disease by RECIST criteria responded well to preoperative imatinib treatment and could undergo R0 resection, with most being evaluated as partial response by CHOI criteria. The optimal reduction in tumor size was achieved with preoperative imatinib treatment for 24 weeks or more. No resumption of imatinib treatment was identified as an independent prognostic factor for recurrence after R0 resection. No additional size criteria for a higher risk of recurrence were identified in this cohort with a size of 10 cm or more.

conclusionsNeoadjuvant imatinib treatment is an effective treatment option for gastric GISTs 10 cm or larger. Postoperative imatinib treatment is recommended even after R0 resection to minimize recurrence.

Indexed as

Gastrointestinal Stromal TumorsImatinib MesylateStomach NeoplasmsAntineoplastic AgentsHumansNeoadjuvant TherapyAntineoplastic AgentsImatinib MesylateGastrointestinal stromal tumorImatinib mesylateNeoadjuvantStomach neoplasm

Identifiers

PMID37351703

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.